COMPANY RESEARCHCRISPR Therapeutics AG
CRISPR Therapeutics is a Swiss-incorporated biotechnology company developing medicines based on gene editing, including edited cell therapies and other genetic approaches. It uses CRISPR technology to investigate treatments for serious diseases, working across research, clinical development and commercialization partnerships. The corporate investor FAQ identifies Zug as its headquarters and Nasdaq ticker CRSP. Its official website and regulatory filings provide current information on its technologies, commercial arrangements and development programs. Genetic medicine and edited-cell technologies form the core of its therapeutic research.
Company at a glance
Corporate information
- Company entity
- CRISPR Therapeutics AG
- Headquarters / principal office
- Switzerland
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://crisprtx.com
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq: CRSP
CRISPR-Cas9 · gene-editing · cell-therapy
hematology · genetic-diseases
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
CRISPR Therapeutics is a Swiss-incorporated biotechnology company developing medicines based on gene editing, including edited cell therapies and other genetic approaches. It uses CRISPR technology to investigate treatments for serious diseases, working across research, clinical development and commercialization partnerships. The corporate investor FAQ identifies Zug as its headquarters and Nasdaq ticker CRSP. Its official website and regulatory filings provide current information on its technologies, commercial arrangements and development programs. Genetic medicine and edited-cell technologies form the core of its therapeutic research.
Business, technology & evidence
- SecuritiesNasdaq: CRSP
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · CRISPR Therapeutics AG ↗CRISPR Therapeutics AG ·
- Official issuer and R&D disclosure · CRISPR Therapeutics AG ↗CRISPR Therapeutics AG ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.